Monopar Therapeutics (MNPR) — 8-K Filings

All 8-K filings from Monopar Therapeutics. Browse 34 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (34)

8-K Filing — Apr 20, 2026
Monopar Therapeutics Files 8-K — Nov 10, 2025 Risk: medium
Monopar Therapeutics Inc. filed an 8-K on November 10, 2025, reporting an event on November 9, 2025. The filing is a current report under the Securities Exchang
Monopar Therapeutics Enters Material Definitive Agreement — Sep 24, 2025 Risk: medium
Monopar Therapeutics Inc. announced on September 23, 2025, that it has entered into a material definitive agreement. The company, incorporated in Delaware with
Monopar Therapeutics Files 8-K — Sep 15, 2025 Risk: low
Monopar Therapeutics Inc. filed an 8-K on September 15, 2025, reporting on its corporate activities. The filing indicates no specific material events or financi
Monopar Therapeutics Files 8-K on Shareholder Vote Matters — Jun 23, 2025 Risk: low
Monopar Therapeutics Inc. filed an 8-K on June 23, 2025, reporting a submission of matters to a vote of security holders on June 17, 2025. The company, incorpor
Monopar Therapeutics Files 8-K — May 13, 2025 Risk: low
Monopar Therapeutics Inc. filed an 8-K on May 13, 2025, reporting on its results of operations and financial condition, as well as financial statements and exhi
Monopar Therapeutics Files 8-K — May 7, 2025 Risk: low
Monopar Therapeutics Inc. filed an 8-K on May 7, 2025, reporting an event that occurred on the same date. The filing is a current report pursuant to Section 13
Monopar Therapeutics Reports Officer/Director Changes & Compensatory Info — Mar 3, 2025 Risk: medium
Monopar Therapeutics Inc. filed an 8-K on March 3, 2025, reporting events as of February 27, 2025. The filing primarily concerns the departure of directors or c
Monopar Therapeutics Relocates Principal Executive Offices — Feb 24, 2025 Risk: low
Monopar Therapeutics Inc. announced on February 19, 2025, a change in its principal executive offices to 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091. This
Monopar Therapeutics Files 8-K: Material Agreement & Equity Sales — Dec 23, 2024 Risk: medium
Monopar Therapeutics Inc. entered into a material definitive agreement on December 20, 2024. The company also reported on unregistered sales of equity securitie
Monopar Therapeutics Files 8-K — Dec 6, 2024 Risk: low
Monopar Therapeutics Inc. filed an 8-K on December 6, 2024, reporting on events that occurred on the same date. The filing primarily concerns financial statemen
Monopar Therapeutics Files 8-K on Financials — Nov 8, 2024 Risk: low
Monopar Therapeutics Inc. filed an 8-K on November 8, 2024, to report on its results of operations and financial condition. The filing includes financial statem
Monopar Therapeutics Files 8-K: Material Agreement — Oct 30, 2024 Risk: medium
Monopar Therapeutics Inc. announced on October 28, 2024, that it entered into a material definitive agreement. The company also disclosed information related to
Monopar Therapeutics Files 8-K: Acquisition, Debt, and Equity Sales — Oct 24, 2024 Risk: medium
On October 23, 2024, Monopar Therapeutics Inc. entered into a material definitive agreement related to the completion of an acquisition. The company also disclo
Monopar Therapeutics Files 8-K — Oct 22, 2024 Risk: low
On October 22, 2024, Monopar Therapeutics Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 1000 Skokie Bl
Monopar Therapeutics Files 8-K — Oct 15, 2024 Risk: low
On October 15, 2024, Monopar Therapeutics Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits
Monopar Therapeutics Files 8-K — Oct 7, 2024 Risk: low
Monopar Therapeutics Inc. filed an 8-K on October 7, 2024, reporting on events that occurred on the same date. The filing is primarily a cover page and does not
Monopar Therapeutics Files 8-K — Sep 12, 2024 Risk: low
Monopar Therapeutics Inc. filed an 8-K on September 12, 2024, reporting an event under Regulation FD Disclosure and Financial Statements and Exhibits. The filin
Monopar Therapeutics Files 8-K Report — Aug 27, 2024 Risk: low
On August 27, 2024, Monopar Therapeutics Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. No
Monopar Therapeutics Files 8-K — Aug 21, 2024 Risk: low
Monopar Therapeutics Inc. filed an 8-K on August 21, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not conta
Monopar Therapeutics Files 8-K — Aug 14, 2024 Risk: low
Monopar Therapeutics Inc. filed an 8-K on August 14, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not conta
Monopar Therapeutics Files 8-K — Jul 9, 2024 Risk: medium
Monopar Therapeutics Inc. filed an 8-K on July 9, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not conta
Monopar Therapeutics Files 8-K — Jun 11, 2024 Risk: low
Monopar Therapeutics Inc. filed an 8-K on June 11, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not cont
Monopar Therapeutics Files 8-K — Jun 10, 2024 Risk: low
On June 10, 2024, Monopar Therapeutics Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. No s
Monopar Therapeutics Appoints New Chief Medical Officer — May 24, 2024 Risk: medium
Monopar Therapeutics Inc. announced on May 23, 2024, the appointment of Dr. Andrew "Andy" Mueller as Chief Medical Officer. Dr. Mueller, who previously served a
Monopar Therapeutics Files 8-K Report — Apr 16, 2024 Risk: low
On April 16, 2024, Monopar Therapeutics Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating potential updates
Monopar Therapeutics Files 8-K — Apr 10, 2024 Risk: low
Monopar Therapeutics Inc. filed an 8-K on April 10, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contai
Monopar Therapeutics Files 8-K — Mar 28, 2024 Risk: low
Monopar Therapeutics Inc. filed an 8-K on March 28, 2024, to report on its results of operations and financial condition. The filing does not contain specific f
Monopar Therapeutics Files 8-K for Regulation FD Disclosure — Mar 7, 2024 Risk: low
Monopar Therapeutics Inc. filed an 8-K on March 7, 2024, to report a Regulation FD Disclosure. The filing does not contain specific financial figures or materia
Monopar Therapeutics Files 8-K: Financials & Exhibits — Mar 5, 2024 Risk: low
On March 5, 2024, Monopar Therapeutics Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating potential updates o
Monopar Therapeutics Faces Potential Delisting Notice — Feb 28, 2024 Risk: high
Monopar Therapeutics Inc. filed an 8-K on February 28, 2024, reporting that on February 27, 2024, it received a notice of delisting or failure to satisfy a cont
Monopar Therapeutics Files 8-K Current Report — Feb 27, 2024 Risk: medium
Monopar Therapeutics Inc. filed an 8-K Current Report on February 27, 2024, disclosing Regulation FD information and Financial Statements and Exhibits. The spec
Monopar Therapeutics Files 8-K for Regulation FD Disclosure — Feb 22, 2024 Risk: low
Monopar Therapeutics Inc. filed an 8-K on February 22, 2024, indicating a Regulation FD Disclosure and Financial Statements and Exhibits. The filing, under SEC
Monopar Therapeutics Files 8-K for Regulation FD Disclosure — Feb 20, 2024 Risk: low
Monopar Therapeutics Inc. filed an 8-K on February 20, 2024, under accession number 0001437749-24-004724. The filing indicates a Regulation FD Disclosure and in

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX